Please use this identifier to cite or link to this item: http://ahro.austin.org.au/austinjspui/handle/1/13530
Title: Angiotensin II receptor antagonists. Potential in elderly patients with cardiovascular disease.
Authors: Burrell, Louise M;Johnston, Colin I
Affiliation: Department of Medicine, University of Melbourne, Austin and Repatriation Medical Centre, Melbourne, Victoria, Australia. burrell@austin.unimelb.edu.au
Issue Date: 1-Jun-1997
Citation: Drugs & Aging; 10(6): 421-34
Abstract: Raised blood pressure in the elderly is not a normal consequences of aging, but is a major risk factor for cardiovascular disease. Cardiac and cerebrovascular disease account for > 50% of deaths among people aged > 65 years. Because the percentage of elderly people in most populations is rising, blood pressure control in this group is becoming increasingly important. Several large intervention studies in the elderly have demonstrated that antihypertensive medication reduces cardiovascular morbidity and mortality. In addition, the absolute benefits of blood pressure reduction are higher in elderly compared with younger patients. ACE inhibitors are effective and well tolerated in the treatment of hypertension in the elderly. Their success led to interest in alternative ways of blocking the renin angiotensin system, and the subsequent development of angiotensin II (AII) receptor antagonists. Losartan was the first drug in this class to become commercially available. Since then, valsartan has been launched in some markets and others are likely to be launched in the near future. Losartan is effective in the treatment of essential hypertension and has a low incidence of adverse effects. First-dose hypotension is very uncommon and, at the present time, cough does not appear to be an adverse effect of these drugs, although long term tolerability studies are needed to confirm this. Angioedema, a rare but life-threatening adverse effect of ACE inhibitors, has also been associated with losartan. Current data suggest that All receptor antagonists are effective in elderly hypertensive patients, although further data are needed to confirm these findings. At present, All receptor antagonists are likely to be used in hypertensive patients who are intolerant of ACE inhibitors, although this may change with the availability of long term tolerability and clinical outcomes data.
Internal ID Number: 9205848
URI: http://ahro.austin.org.au/austinjspui/handle/1/13530
URL: http://www.ncbi.nlm.nih.gov/pubmed/9205848
Type: Journal Article
Subjects: Aged
Aged, 80 and over
Aging.physiology
Angiotensin Receptor Antagonists
Angiotensin-Converting Enzyme Inhibitors.administration & dosage.pharmacology.therapeutic use
Antihypertensive Agents.administration & dosage.pharmacology.therapeutic use
Biphenyl Compounds.administration & dosage.pharmacology.therapeutic use
Blood Pressure.drug effects.physiology
Cardiovascular Diseases.drug therapy.physiopathology
Clinical Trials as Topic
Heart Failure.drug therapy.physiopathology
Humans
Hypertension.drug therapy.physiopathology
Imidazoles.administration & dosage.pharmacology.therapeutic use
Kidney Diseases.drug therapy.physiopathology
Losartan
Renin-Angiotensin System.drug effects
Tetrazoles.administration & dosage.pharmacology.therapeutic use
Valine.administration & dosage.analogs & derivatives.pharmacology.therapeutic use
Appears in Collections:Journal articles

Files in This Item:
There are no files associated with this item.


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.